Patents by Inventor Dirk Schenk
Dirk Schenk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10315352Abstract: The invention relates to devices and to methods for transporting preforms in the region of a blow-molding machine, in particular a sorting device (10) for transporting preforms (20) composed of a thermoplastic material in the region of a blow-molding machine for the blow-molding of containers, comprising a transportation wheel (12), which has a plurality of accommodating recesses (18) for accommodating and conveying the preforms (20), which accommodating recesses are arranged on the circumference of the transportation wheel in such a way that the accommodating recesses are distributed in the circumferential direction, a guide collar (16), which extends circumferentially around the transportation wheel (12) in some regions in such a way that the guide collar is radially spaced apart from the transportation wheel, wherein the preforms (20) are transported in suspension between the transportation wheel (12) and the guide collar (16) in the region of the sorting device (10), and a selection unit for selectively rType: GrantFiled: August 11, 2015Date of Patent: June 11, 2019Assignees: KHS Corpoplast GmbH, KHS GmbHInventors: Rolf Baumgarte, Michael Linke, Frank Lewin, Dirk Schenk
-
Patent number: 10214553Abstract: The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.Type: GrantFiled: June 12, 2015Date of Patent: February 26, 2019Assignees: TEVA PHARMACEUTICALS INTERNATIONAL GMBH, RATIOPHARM GMBHInventors: Wolfgang Albrecht, Judith Aronhime, Brijnath P. Chaurasia, Jens Geier, Richard Guserle, Julia Hrakovsky, Claudia Lauer, Ramkaran Prajapati, Vinod K. Kansal, Pavan V. Kumar, Hans-Juergen Mika, Siva Rama Krishna Muppalla, Marina Ratkaj, Roman Safonov, Dirk Schenk, Naveen C. Srivastav, Ralph Stefan, Ashish Tripathi
-
Publication number: 20170252960Abstract: The invention relates to devices and to methods for transporting preforms in the region of a blow-molding machine, in particular a sorting device (10) for transporting preforms (20) composed of a thermoplastic material in the region of a blow-molding machine for the blow-molding of containers, comprising a transportation wheel (12), which has a plurality of accommodating recesses (18) for accommodating and conveying the preforms (20), which accommodating recesses are arranged on the circumference of the transportation wheel in such a way that the accommodating recesses are distributed in the circumferential direction, a guide collar (16), which extends circumferentially around the transportation wheel (12) in some regions in such a way that the guide collar is radially spaced apart from the transportation wheel, wherein the preforms (20) are transported in suspension between the transportation wheel (12) and the guide collar (16) in the region of the sorting device (10), and a selection unit for selectively rType: ApplicationFiled: August 11, 2015Publication date: September 7, 2017Inventors: Rolf BAUMGARTE, Michael LINKE, Frank LEWIN, Dirk SCHENK
-
Publication number: 20170137453Abstract: The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.Type: ApplicationFiled: June 12, 2015Publication date: May 18, 2017Applicant: ratiopharm GmbHInventors: Wolfgang ALBRECHT, Judith ARONHIME, Brijnath P. CHAURASIA, Jens GEIER, Richard GUSERLE, Julia HRAKOVSKY, Claudia LAUER, Ramkaran PRAJAPATI, Vinod K. KANSAL, Pavan V. KUMAR, Hans-Juergen MIKA, Siva Rama Krishna MUPPALLA, Marina RATKAJ, Roman SAFONOV, Dirk SCHENK, Naveen C. SRIVASTAV, Ralph STEFAN, Ashish TRIPATHI
-
Publication number: 20170071869Abstract: The subject invention provides an oral patch comprising: a) a liner; and b) a film composition thereon, the film composition comprising (i) laquinimod in an amount of about 0.1%-20% by weight of the film composition, and (ii) one or more film forming agents in a total amount of about 40%-90% by weight of the film composition. The subject invention also provides a method for delivering laquinimod across the oral mucosa of a subject, or for treating a human subject afflicted with a form of multiple sclerosis, comprising periodically administering to the human subject an oral patch as described herein. The subject invention also provides an oral patch as described herein for use in treating a human subject afflicted with a form of multiple sclerosis.Type: ApplicationFiled: March 13, 2015Publication date: March 16, 2017Applicant: Teva Pharmaceutical Industries Ltd.Inventors: Ralph Stefan, Hans Juergen Mika, Claudia Lauer, Dirk Schenk, Sabine Prohl
-
Publication number: 20160038435Abstract: This invention provides a transdermal patch comprising a) a backing layer; b) a liner; c) optionally, a highly porous membrane; and d) a pharmaceutical composition comprising: (i) optionally, a pressure sensitive adhesive in an amount of up to about 95 wt % of the pharmaceutical composition, (ii) laquinimod in an amount of about 0.1-20 wt % of the pharmaceutical composition, and (iii) optionally, one or more permeation enhancers in a total amount of up to about 70 wt % of the pharmaceutical composition. This invention also provides a method for delivering laquinimod across the skin of the subject and for treating a human subject afflicted with a form of multiple sclerosis comprising administering to the skin of the subject a transdermal patch as described herein. This invention further provides a transdermal patch as described herein for use in treating a human subject afflicted with a form of multiple sclerosis.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Applicant: Teva Pharmaceutical Industries Ltd.Inventors: Ralph STEFAN, Hans-Juergen MIKA, Tanja PRIES, Dirk SCHENK, Sabine PROHL
-
Publication number: 20150335658Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: July 29, 2015Publication date: November 26, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Jochen SCHUMACHER, Manfred SUESSE, Michael DITTGEN, Stephan MLETZKO, Jan-Peter INGWERSEN, Thomas LANGGUTH, Dirk SCHENK, Hubert KAFFL
-
Patent number: 9095691Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: March 15, 2013Date of Patent: August 4, 2015Assignee: Bayer Intellectual Property GmbHInventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Patent number: 9005653Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: GrantFiled: December 27, 2013Date of Patent: April 14, 2015Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Publication number: 20140109916Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: ApplicationFiled: December 27, 2013Publication date: April 24, 2014Applicant: Bayer Intellectual Property GmbHInventors: Thomas LANGGUTH, Stefan BRACHT, Michael DITTGEN, Petra HUBER, Dirk SCHENK
-
Patent number: 8668925Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: GrantFiled: December 10, 2004Date of Patent: March 11, 2014Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Patent number: 8486443Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: February 4, 2004Date of Patent: July 16, 2013Assignee: Bayer IP GmbHInventors: Jochen Schuhmacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20070243240Abstract: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.Type: ApplicationFiled: March 24, 2005Publication date: October 18, 2007Inventors: Fred Windt-Hanke, Clemens Gunther, Reinhard Horowski, Johannes Tack, Adalbert Engfer, Katalin Bostedt, Dirk Schenk
-
Publication number: 20070134309Abstract: The invention relates to a transdermal therapeutic system containing ergolin compounds, preferably lisuride, in which the ergolin compound is stabilized. The oxidation-sensitive ergolin compound is stabilized by a combination of at least one liposoluble, free radical-scavenging antioxidant, preferably di-tert.-butyl methyl phenol, di-tert.-butyl metoxy phenol, tocopherol or ubiquinone and a basic polymer.Type: ApplicationFiled: May 30, 2004Publication date: June 14, 2007Inventors: Reinhard Horowski, Johannes Tack, Katalin Bostedt, Dirk Schenk
-
Publication number: 20060251707Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: February 4, 2004Publication date: November 9, 2006Inventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20060105030Abstract: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.Type: ApplicationFiled: March 24, 2005Publication date: May 18, 2006Inventors: Fred Windt-Hanke, Clemens Gunther, Reinhard Horowski, Johannes Tack, Adalbert Engfer, Katalin Bostedt, Dirk Schenk
-
Publication number: 20050220855Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome.Type: ApplicationFiled: April 28, 2005Publication date: October 6, 2005Inventors: Reinhard Horowski, Johannes Tack, Fred Windt-Hanke, Clemens Gunther, Adalbert Engfer, Katalin Bostedt, Dirk Schenk
-
Publication number: 20050142175Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: ApplicationFiled: December 10, 2004Publication date: June 30, 2005Inventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Publication number: 20040208917Abstract: This present invention concerns transdermal systems for the release of clonidine, characterized in that the clonidine is contained in an adhesive layer on the basis of a styrene block polymer, as well as its use in the treatment of hypertonia, migraines, anxieties, hyperkinetic behavioral disorders, alcohol or drug-related withdrawal symptoms, and menopausal symptoms.Type: ApplicationFiled: April 16, 2003Publication date: October 21, 2004Inventors: Wilfried Fischer, Dirk Schenk
-
Publication number: 20040166148Abstract: The invention concerns a transdermal therapeutic delivery system (TTDS) with butenolide.Type: ApplicationFiled: February 3, 2004Publication date: August 26, 2004Inventors: Dirk Schenk, Elisabeth Meyer, Angelika Woess, Sarah McLeod